Pleased to announce £4.24m follow-on financing. Existing investors Epidarex Capital, who led the round, & Scottish Enterprise, & new investor Caribou Property Limited liz Full release here (macomics.com/2021/07/29/mac…). #Edinburgh #Cambridge #drugdiscovery #Biotechnology

Our leadership team is expanded with the appointment of Carola Ries who joins as Chief Scientific Officer after 16 years at Roche, to lead our macrophage-based therapeutics R&D. Welcome. Full release including our £4.24m follow-on financing (macomics.com/2021/07/29/mac…).

Welcome to our new R&D team members #MoritzHaneklaus #CarmenRodriguezSeoane #ChantellPayton #ConorPoland #SadieKemp. Full release here (macomics.com/wp-content/upl…). #lifesciences #oncology #cancer #drugdiscovery #appointment #expansion #Cambridge #macrophage #Edinburgh

Our Co-Founder and VP Immunology, Luca Cassetta will be presenting at the ImmunoUK: In person by Oxford Global on #macrophage biology. We’re delighted to be able to present in person once again. To find out more about the event: bit.ly/3p5w9JV

#Congratulations - our co-founder and VP Immunology, Dr Luca Cassetta has been honoured with the Society for Immunotherapy of Cancer ‘Best Immunotherapy Biomarkers Paper Award’ for this publication jitc.bmj.com/content/8/2/e0… #SITC21 #Immunotherapy #Cancer

Our co-founder Prof. Jeffery Pollard has been named on the annual Highly Cited Researchers™ 2021 list from Clarivate for Academia & Government. His ground-breaking research demonstrates the role of #macrophages in disease. #congratulations #HighlyCited2021 #immunotherapy #cancer

Summer is over, conference season is here. We’ll be attending a number of business & scientific conferences in the coming months: read full list here macomics.com/2022/09/05/mac…. Reach out if you’d like to meet us for an update on our progress #macrophage #drugdiscovery #Immunology

Congratulations to our talented runners Alicia Poindron, Chantell Payton, Amber Ngo, Moritz Haneklaus, and Krzysztof Wicher who completed the #Cambridge Chariots of Fire run this weekend in aid of Arthur Rank Hospice👏 🥳 Donate here justgiving.com/fundraising/ma…

Our Co-Founder and VP Immunology, Luca Cassetta is speaking at #ImmunoUK by Oxford Global on 28-29 March. Luca will share our precision medicine approach which modulates #macrophage biology as an innovative #cancer treatment. Find out more: oxfordglobal.co.uk/immuno-series-…

With great sadness we announce the passing of our Founder, Director and Adviser, Professor Jeff W. Pollard, on 1 May 2023. He died peacefully at home after struggling against cancer.

Passionate about developing novel therapies targeting tumour-associated macrophages, he leaves a huge legacy to the cancer research community and to the world of macrophage biology.

Delighted to announce that Macomics has been seleted as a finalist for the ON Helix BioNewsRound Award 2023 linkedin.com/posts/one-nucl…

We are thrilled to be shortlisted in this year's BioNewsRound awards. Voting is now open - click here lnkd.in/eSt_TMxN

Less than a week to go to vote for Macomics in the One Nucleus #BioNewsRound #awards 2023 for the news of our deal with 小野薬品工業株式会社 - voting is just one click away app.sli.do/event/xBbQ94pZ…